For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Biogen Idec, Inc.

USPTO Granted Patents = 46

% Expired Patents = 52.2

CIPO Patents = 5

EPO Patents = 9

Trademarks = 2

Forward Citations = 1,011

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Nabil Hanna (23 out of 40 patents)

Darrell R Anderson (14 out of 22 patents)

Peter Brams (12 out of 24 patents)

4. Mitchell E Reff (7 out of 25 patents)

5. Roland A Newman (7 out of 30 patents)

6. Antonio J Grillo-Lopez (6 out of 9 patents)

7. Christine A White (5 out of 9 patents)

8. John G Curd (5 out of 8 patents)

9. William H Rastetter (4 out of 18 patents)

10. Kandasamy Hariharan (3 out of 12 patents)

11. Paul Chinn (3 out of 7 patents)

12. Gary R Braslawsky (3 out of 4 patents)

13. Amelia Nancy Black (3 out of 15 patents)

14. Antonio J Grillo-López (2 out of 3 patents)

15. Alan M Sonnenfeld (2 out of 2 patents)

Core Competencies:

Anti-CD20 Antibodies

Anti-CD80 Antibodies

B-Cell Lymphoma

Chronic Lymphocytic Leukemia

Pemphigus Treatment

Hematologic Malignancies

Immunosuppression

Rheumatoid Arthritis

Depth Filtration

Polypeptide Purification

Chimeric Antibodies

Cancer Therapies

46 patents: Sort by Forward Citations

1. 9993550 - Treatment of pemphigus (2018-06-12),

2. 8821873 - Treatment of diffuse large-cell lymphoma with anti-CD20 antibody (2014-09-02),

3. 8608960 - Method of purifying polypeptides by simulated moving bed chromatography (2013-12-17),

4. 8557244 - Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody (2013-10-15),

5. 8545843 - Treatment of vasculitis (2013-10-01),

6. 8329172 - Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody (2012-12-11),

7. 8206711 - Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies (2012-06-26),

8. 7820161 - Treatment of autoimmune diseases (2010-10-26),

9. 7759117 - Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures (2010-07-20),

10. 7744877 - Expression and use of anti-CD20 Antibodies (2010-06-29),

11. 7682612 - Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody (2010-03-23),

12. 7604989 - Inhibition of apoptosis process and improvement of cell performance (2009-10-20),

13. 7510713 - Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies (2009-03-31),

14. 7510712 - Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies (2009-03-31),

15. 7501264 - Methods of producing 7C10 and 16C10 CD80-specific antibodies (2009-03-10),

Biogen Idec, Inc. is a leading biotechnology company based in Cambridge, MA, specializing in the development of innovative therapies for neurological and neurodegenerative diseases. The company focuses on advanced research in anti-CD20 antibodies, chimeric antibodies, and recombinant antibodies, targeting conditions such as B-cell lymphomas and autoimmune diseases. Biogen is committed to addressing unmet medical needs through its expertise in gene integration and hematologic malignancies, positioning itself as a key player in the biopharmaceutical landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

46 Patents

#59 in Cambridge, MA

#425 in Massachusetts

#7,585 in US

#15,085 in the World

Cambridge, MA, United States of America

Biogen Idec, Inc.

Forward Citations = 1,011

62 inventors:

Nabil Hanna (23 out of 40 patents)

Darrell R Anderson (14 out of 22 patents)

Peter Brams (12 out of 24 patents)

4. Mitchell E Reff (7 out of 25 patents)

5. Roland A Newman (7 out of 30 patents)

Please report any incorrect information to [email protected]

Loading…